Monopar Therapeutics Inc.
MNPR
$59.27
-$1.72-2.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.20M | -3.44M | -2.45M | -2.63M | -10.93M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 387.60K | 1.10M | 1.28M | 1.36M | 4.82M |
| Change in Net Operating Assets | 1.44M | 247.90K | 96.60K | -4.39M | 4.11M |
| Cash from Operations | -3.37M | -2.09M | -1.08M | -5.66M | -2.00M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -62.19M | -2.13M | 1.19M | -325.80K | -14.34M |
| Cash from Investing | -62.19M | -2.13M | 1.19M | -325.80K | -14.34M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 127.77M | 4.70K | 15.40K | 56.20M |
| Repurchase of Common Stock | -384.70K | -35.38M | -321.60K | -131.10K | -66.90K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -384.70K | 92.39M | -316.80K | -115.70K | 56.14M |
| Foreign Exchange rate Adjustments | 99.50K | 400.00 | -2.60K | -100.00 | -3.80K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -- | -- | -- |
| Net Change in Cash | -65.84M | 88.18M | -209.50K | -6.10M | 39.80M |